Qianjiang Yongan Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Qianjiang Yongan Pharmaceutical CEO'su Rengui Hong, Jun2021 tarihinde atandı, in görev süresi 3.42 yıldır. şirketin hisselerinin 0.062% doğrudan sahiptir ve bu hisselerin değeri CN¥ 1.54M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.8 yıl ve 3.4 yıldır.

Anahtar bilgiler

Rengui Hong

İcra Kurulu Başkanı

CN¥1.9m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.4yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	8.8yrs
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Rengui Hong (41 yo)

3.4yrs

Görev süresi

CN¥1,909,100

Tazminat

Mr. Rengui Hong is Managing Director and Director of Qianjiang Yongan Pharmaceutical Co. Ltd. from June 28, 2021.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rengui Hong	MD & Director	3.4yrs	CN¥1.91m	0.062% CN¥ 1.5m
Baineng Luo	Head of the Audit Department	8.2yrs	CN¥522.50k	0.062% CN¥ 1.5m
Shi Hao Dong	Deputy General Manager	18.7yrs	CN¥1.09m	0.37% CN¥ 9.3m
Xiquan Fang	Deputy General Manager	11.3yrs	CN¥1.74m	0.097% CN¥ 2.4m
Zhihua Wang	Deputy General Manager	9.4yrs	CN¥918.30k	0.097% CN¥ 2.4m
Shaobo Li	Senior Management	5.8yrs	CN¥627.70k	0.017% CN¥ 423.8k

8.8yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: 002365 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rengui Hong	MD & Director	3.4yrs	CN¥1.91m	0.062% CN¥ 1.5m
Yong Chen	Chairman	18.7yrs	CN¥2.95m	21.79% CN¥ 543.3m
Yuxi Wu	Chairman of the Supervisory Board	3.4yrs	CN¥166.70k	0.19% CN¥ 4.7m
Chunxiang Zhao	Independent Director	3.4yrs	CN¥80.00k	Veri yok
Bing Zhang	Independent Director	3.4yrs	CN¥80.00k	Veri yok
Xu Wu	Supervisor	9.4yrs	Veri yok	Veri yok
Zidi Chen	Non-Independent Director	less than a year	CN¥367.60k	Veri yok
Wen Chen	Independent Director	less than a year	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002365 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Qianjiang Yongan Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.034 loss in 3Q 2023)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.14 in 2Q 2023)

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.097 (vs CN¥0.051 in 1Q 2023)

Full year 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.48 profit in FY 2022)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment deteriorates as stock falls 19%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.15 profit in 3Q 2022)

New minor risk - Profit margin trend

Full year 2022 earnings released: EPS: CN¥0.48 (vs CN¥0.38 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.13 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.027 (vs CN¥0.017 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.37 (vs CN¥0.31 in FY 2019)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥8.66

New 90-day low: CN¥9.00

New 90-day low: CN¥10.03

Third quarter earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥10.91

New 90-day low: CN¥11.63

Earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş